Navigation Links
Key bone marrow protein identified as potential new leukemia treatment target
Date:4/15/2013

(WASHINGTON, April 15, 2013) A new study on how the progression of acute lymphocytic leukemia (ALL) is influenced by the bone marrow environment has demonstrated for the first time that targeting a specialized protein known as osteopontin (OPN) may be an effective strategy to increase the efficacy of chemotherapy in patients with this type of blood cancer. Study data were published online today in Blood, the Journal of the American Society of Hematology (ASH).

Acute lymphocytic leukemia (ALL) is a cancer of white blood cells, which normally fight infection in the body. ALL develops when abnormal white blood cells grow quickly but do not properly develop, crowding out normal cells and inhibiting healthy function. While patients with ALL typically experience good initial responses to treatment with chemotherapy, many suffer relapses and their disease becomes extremely difficult to treat (refractory) when a small percentage of abnormal cells reemerge after having evaded the effects of the cytotoxic drug. Relapsed disease arises from residual malignant cells below the level of detection at the time the patient has his or her initial response (a condition known as minimal residual disease or MRD).

Treatment strategies aimed at combating chemotherapy resistance and reducing MRD may have the potential to increase overall survival.

Previous studies have demonstrated that, even when MRD is not completely eradicated, a reduction in MRD burden correlates with significantly higher overall survival. One proposed approach to improving chemotherapy efficacy and reducing MRD includes identifying lingering, dormant leukemic cells and forcing them into active cell division to make them responsive to treatment, since chemotherapy targets cells that are rapidly dividing.

"Previous studies have suggested that osteopontin (OPN), a protein present in the bone marrow, may regulate the way tumor cells grow and spread throughout the body; however, its specific role in the progression of leukemia has not been well studied," said study author Dorothy Sipkins, MD, PhD, of the Section of Hematology/Oncology at the University of Chicago. "Our research aimed to understand the interactions of OPN and leukemic cells in specific areas of the bone marrow, known as niches, which may allow the cells to 'hide' in the dormant state and evade the effects of chemotherapy."

To better understand the interactions of the leukemic cells and OPN within these bone marrow niches and whether leukemic cells can hide, remain dormant, and evade chemotherapy, Dr. Sipkins and colleagues conducted a series of analyses and experiments in mouse models. They further evaluated how controlling the expression of OPN would affect the activity of the leukemic cells and how that control may better sensitize the leukemic cells to the effects of chemotherapy.

Dr. Sipkins' team found that inhibiting the interaction of the OPN with leukemic cells in the bone marrow niches led the dormant cells to actively proliferate, which allows the chemotherapy to identify and target them. When OPN was blocked using neutralizing antibodies and then followed by chemotherapy treatment, leukemic cells responded to the chemotherapy and overall MRD was significantly reduced. These data suggest that OPN may serve as an anchor for leukemic cells within areas of the bone marrow that allow the cells to remain dormant, encouraging them to localize to these areas.

"After examining the interactions between the leukemic cells, OPN, and the bone marrow microenvironment, we learned that the bone marrow environment can promote leukemia cell dormancy, creating a form of resistance to chemotherapy. This is an important target, because if we can disrupt the interaction between the OPN and the leukemic cells, we may be able to make this disease more responsive to chemotherapy," said Dr. Sipkins. "We've traditionally designed therapies that focus solely on the cancer cells, but future strategies for ALL and other blood cancer treatment may be enhanced by targeting not just the cancer cells but the environment with which the cells interact."

Dr. Sipkins and her team further suggest that in order to develop a leukemia treatment that neutralizes OPN, studies would need to assess the potential toxic side effects on normal stem cells that cohabit the bone marrow microenvironment.

Alternatively, a therapy could be developed to reinforce the interaction between OPN and leukemia cells, which would help maintain the dormant state in an effort to prevent or slow disease progression.


'/>"/>

Contact: Andrea Slesinski
aslesinski@hematology.org
202-552-4927
American Society of Hematology
Source:Eurekalert

Related medicine news :

1. Fertilizing bone marrow helps answer why some cancers spread to bones
2. Markey receives $6.25 million to study deadly blood and bone marrow disease
3. HIV Drug May Prevent Bone Marrow Transplant Complication
4. HIV drug reduces graft-vs.-host disease in bone marrow transplant patients, Penn study shows
5. Clinical trial seeks to cure advanced Crohns disease using bone marrow transplant
6. Bone marrow transplant eliminates signs of HIV infection
7. HIV Undetectable in 2 Men After Bone Marrow Transplants: Study
8. New genetic clues to why most bone marrow transplant patients develop graft-versus-host disease
9. Lack of sleep affects bone health and bone marrow activity
10. Half-match bone marrow transplants wipe out sickle cell disease in selected patients
11. Half-Match Marrow Transplants Help Some With Sickle Cell
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... ... May 04, 2016 , ... NCPDP announced ... on Tuesday with Frank Luntz, sharing a dynamic, bi-partisan environmental scan of healthcare-related ... dive on NCPDP’s model solution to help stem the tide of the opioid ...
(Date:5/4/2016)... NY (PRWEB) , ... May 04, 2016 , ... ... non-profit organization devoted exclusively to funding innovative lymphoma research and serving the lymphoma ... – is set to return to the esteemed Quaker Ridge Golf Club in ...
(Date:5/4/2016)... (PRWEB) , ... May 04, 2016 , ... The ... Day to recognize chaplains for their valuable support to patients and their families, and ... May 10. , To mark Spiritual Care Day, SCA has sent “Thank You Chaplain” ...
(Date:5/4/2016)... Charles, LA (PRWEB) , ... May 04, 2016 , ... ... Charles, LA area has teamed up with Big Brothers Big Sisters of Southwest Louisiana ... now being accepted here . , Big Brothers Big Sisters of Southwest Louisiana ...
(Date:5/4/2016)... ... May 04, 2016 , ... ... SS&A teamed up with one of the top website design companies to create ... informative legal articles related to the law firm's main practice areas. These practice ...
Breaking Medicine News(10 mins):
(Date:5/4/2016)... May 4, 2016 BiondVax Pharmaceuticals Ltd. ... Ron Babecoff , will be attending the Joseph Gunnar ... . On Thursday, May 5, Dr. Babecoff will ... by Joseph Gunner & Co, taking place at ... that Dr. Babecoff will be using is downloadable from BiondVax,s ...
(Date:5/4/2016)... Jersey , May 4, 2016 ... successful completion of an alternative public offering (APO). This ... owned operating company, Valeritas, Inc. and a private placement ... stock at $5.00 per share. Under the ... May 3, 2016, Valeritas Holdings, Inc. will trade on ...
(Date:5/4/2016)... Research and Markets has ... Keratosis Market and Competitive Landscape Highlights - ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ... Highlights 2016, provides comprehensive insights into Actinic ... Keratosis market valuations and forecast, Actinic Keratosis ...
Breaking Medicine Technology: